scholarly journals Proapoptotic and Antiproliferative Effects ofThymus caramanicuson Human Breast Cancer Cell Line (MCF-7) and Its Interaction with Anticancer Drug Vincristine

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Saeed Esmaeili-Mahani ◽  
Farzaneh Falahi ◽  
Mohammad Mehdi Yaghoobi
Keyword(s):  
Breast Cancer ◽  
Cyclin D1 ◽  
Cancer Cells ◽  
Anticancer Drug ◽  
Human Breast Cancer ◽  
Breast Cancer Cells ◽  
Caspase 3 ◽  
Human Breast Cancer Cells ◽  
Human Breast ◽  
Mcf 7

Thymus caramanicus Jalasis one of the species of thymus that grows in the wild in different regions of Iran. Traditionally, leaves of this plant are used in the treatment of diabetes, arthritis, and cancerous situation. Therefore, the present study was designed to investigate the selective cytotoxic and antiproliferative properties ofThymus caramanicusextract (TCE). MCF-7 human breast cancer cells were used in this study. Cytotoxicity of the extract was determined using MTT and neutral red assays. Biochemical markers of apoptosis (caspase 3, Bax, and Bcl-2) and cell proliferation (cyclin D1) were evaluated by immunoblotting. Vincristine was used as anticancer control drug in extract combination therapy. The data showed that incubation of cells with TCE (200 and 250 μg/mL) significantly increased cell damage, activated caspase 3 and Bax/Bcl2 ratio. In addition, cyclin D1 was significantly decreased in TCE-treated cells. Furthermore, concomitant treatment of cells with extract and anticancer drug produced a significant cytotoxic effect as compared to extract or drugs alone. In conclusion, thymus extract has a potential proapoptotic/antiproliferative property against human breast cancer cells and its combination with chemotherapeutic agent vincristine may induce cell death effectively and be a potent modality to treat this type of cancer.

scholarly journals Stabilization of cyclin D1 mRNA via the phosphatidylinositol 3-kinase pathway in MCF-7 human breast cancer cells

2000 ◽  
Vol 166 (2) ◽  
pp. 329-338 ◽  
Author(s):  
B Dufourny ◽  
HA van Teeffelen ◽  
IH Hamelers ◽  
JS Sussenbach ◽  
PH Steenbergh
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Cyclin D1 ◽  
Cancer Cells ◽  
Human Breast Cancer ◽  
Breast Cancer Cells ◽  
Human Breast Cancer Cells ◽  
Human Breast ◽  
Phosphatidylinositol 3 Kinase ◽  
Mcf 7

Treatment of quiescent MCF-7 human breast cancer cells with either the polypeptide growth factors insulin-like growth factor-I (IGF-I) or epidermal growth factor (EGF), the steroid hormone estradiol (E2) or the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) results in increased steady-state levels of cyclin D1 mRNA and protein. Unexpectedly, this elevation of cyclin D1 expression by all of these agents is inhibited by the specific phosphatidylinositol 3-kinase (PI3-K) inhibitor LY294002. Since transcriptional activation of the cyclin D1 promoter by EGF, E2 and TPA is independent of PI3-K activity, these findings suggest a post-transcriptional role for PI3-K in the regulation of cyclin D1 expression. Here we show that inhibition of PI3-K by LY294002 decreases the half-life of the 4.5 kb cyclin D1 mRNA species. In contrast, the stability of the 1.5 kb cyclin D1 mRNA is not affected by PI3-K inhibition. PI3-K-mediated stabilization of mRNA is not a general phenomenon, since other rapidly regulated and unstable mRNAs, such as those encoding c-fos, c-jun and c-myc, are not stabilized upon activation of the PI3-K signaling pathway.

Sign in / Sign up

Export Citation Format

Share Document